Preventive and therapeutic reduction of amyloid deposition and behavioral impairments in a model of Alzheimer’s disease by whole blood exchange

被引:0
|
作者
Akihiko Urayama
Ines Moreno-Gonzalez
Diego Morales-Scheihing
Vineetkumar Kharat
Sandra Pritzkow
Claudio Soto
机构
[1] McGovern Medical School,Mitchell Center for Alzheimer’s disease and related Brain disorders, Department of Neurology
[2] University of Texas Health Science Center at Houston,Department of Cell Biology, Genetic and Physiology, Faculty of Sciences, Instituto de Investigacion Biomedica de Malaga
[3] University of Malaga,IBIMA, Networking Research Center on Neurodegenerative Diseases (CIBERNED)
来源
Molecular Psychiatry | 2022年 / 27卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) is the major form of dementia in the elderly population. The main neuropathological changes in AD patients are neuronal death, synaptic alterations, brain inflammation, and the presence of cerebral protein aggregates in the form of amyloid plaques and neurofibrillary tangles. Compelling evidence suggests that the misfolding, aggregation, and cerebral deposition of amyloid-beta (Aβ) plays a central role in the disease. Thus, prevention and removal of misfolded protein aggregates is considered a promising strategy to treat AD. In the present study, we describe that the development of cerebral amyloid plaques in a transgenic mice model of AD (Tg2576) was significantly reduced by 40–80% through exchanging whole blood with normal blood from wild type mice having the same genetic background. Importantly, such reduction resulted in improvement in spatial memory performance in aged Tg2576 mice. The exact mechanism by which blood exchange reduces amyloid pathology and improves memory is presently unknown, but measurements of Aβ in plasma soon after blood exchange suggest that mobilization of Aβ from the brain to blood may be implicated. Our results suggest that a target for AD therapy may exist in the peripheral circulation, which could open a novel disease-modifying intervention for AD.
引用
收藏
页码:4285 / 4296
页数:11
相关论文
共 50 条
  • [31] Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer's disease model mice
    Hosokawa, Masato
    Tanaka, Yoshinori
    Arai, Tetsuaki
    Kondo, Hiromi
    Akiyama, Haruhiko
    Hasegawa, Masato
    EXPERIMENTAL ANIMALS, 2018, 67 (01) : 63 - 70
  • [32] Gut microbiota regulate cognitive deficits and amyloid deposition in a model of Alzheimer's disease
    Li, Zhuo
    Zhu, Hua
    Guo, Yaxi
    Du, Xiaopeng
    Qin, Chuan
    JOURNAL OF NEUROCHEMISTRY, 2020, 155 (04) : 448 - 461
  • [33] Conditional inactivation of nicastrin restricts amyloid deposition in an Alzheimer's disease mouse model
    Sesele, Katia
    Thanopoulou, Kalliopi
    Paouri, Evi
    Tsefou, Eliona
    Klinakis, Apostolos
    Georgopoulos, Spiros
    AGING CELL, 2013, 12 (06) : 1032 - 1040
  • [34] Thrombospondin 4 reduces amyloid deposition in a mouse model of Alzheimer's disease.
    Maillet, M.
    Molkentin, J. D.
    MOLECULAR BIOLOGY OF THE CELL, 2016, 27
  • [35] Therapeutic strategies for treatment of Alzheimer's disease aimed at reduction of beta-amyloid production
    Schenk, D
    Freedman, S
    Dovey, R
    Knops, J
    Games, D
    JohnsonWood, K
    Seubert, P
    JOURNAL OF NEUROCHEMISTRY, 1997, 69 : S104 - S104
  • [36] Chronic sleep fragmentation exacerbates amyloid β deposition in Alzheimer's disease model mice
    Minakawa, Eiko N.
    Miyazaki, Koyomi
    Maruo, Kazushi
    Yagihara, Hiroko
    Fujita, Hiromi
    Wada, Keiji
    Nagai, Yoshitaka
    NEUROSCIENCE LETTERS, 2017, 653 : 362 - 369
  • [37] CHANGE IN ALZHEIMER'S DISEASE BLOOD-BASED BIOMARKERS AND ASSOCIATIONS WITH BRAIN AMYLOID DEPOSITION
    Pike, James
    Lu, Yifei
    Chen, Jinyu
    Walker, Keenan
    Sullivan, Kevin
    Griswold, Michael
    Mosley, Thomas
    Palta, Priya
    INNOVATION IN AGING, 2024, 8 : 2 - 2
  • [38] Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease
    Li, Wei-Wei
    Shen, Ying-Ying
    Tian, Ding-Yuan
    Bu, Xian-Le
    Zeng, Fan
    Liu, Yu-Hui
    Chen, Yang
    Yao, Xiu-Qing
    Li, Hui-Yun
    Chen, Dong-Wan
    Zhou, Fa-Ying
    Yang, Heng
    Li, Qi-Ming
    Bao, Wei-Qi
    Guan, Yi-Hui
    Zhou, Hua-Dong
    Jin, Rong-Bing
    Wang, Yan-Jiang
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 69 (01) : 169 - 178
  • [39] Quantifying an amyloid β model for Alzheimer's disease
    Schneider, Lon S.
    LANCET NEUROLOGY, 2013, 12 (04): : 327 - 328
  • [40] Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach
    Behl, C
    Moosmann, B
    FREE RADICAL BIOLOGY AND MEDICINE, 2002, 33 (02) : 182 - 191